Jefferies' Holz: Pfizer, Mylan deal not seen as defensive, both business in 'tight spaces'

Jared Holz, health care sector strategist at Jefferies, and Chris Meekins, research analyst at Raymond James, join CNBC's "Closing Bell" to discuss the new deal between Pfizer and Mylan, as well as presidential hopeful Sen. Kamala Harris' new healthcare plan.